Riskpilot← Back to searchSign inGet full accessCirqle Biomedical Holding ApS
APSActiveCVR 39849585Frederiksberg Bredegade 3C, 5.Activities of holding companies · NACE 6421Est. 2018— employees
Revenue 2024
DKK -12K
+86% vs 2023
EBITDA margin
100.0%
-86% vs 2023
Equity ratio
57.8%
Financial strength
Net profit 2024
DKK 12,9M
+72678% vs 2023
| Revenue | DKK -12K | +86% |
| EBITDA | DKK -12K | -86% |
| Net profit | DKK 12,9M | +72678% |
| Total assets | DKK 1,2M | -70% |
| Equity | DKK 715K | +23232% |
| Employees | — | — |
Legal name
Cirqle Biomedical Holding ApS
CVR number
39849585
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
10. september 2018
Share capital
DKK 50.002
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at eje kapitalandele i selskaber, som beskæftiger sig med kommercialisering af biomedicinsk teknologi.
Address
Frederiksberg Bredegade 3C, 5.
Phone
+4526831750
Email
frederik.madsen@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -7 | -7 | -10 | -7 | -12 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -7 | -7 | -10 | -7 | -12 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -7 | -7 | -10 | -7 | -12 |
| Net financials | -3 | -5 | -3 | -16 | 13.049 |
| Profit before tax | -10 | -12 | -13 | -22 | 13.037 |
| Tax | -0 | -0 | -8 | -4 | 88 |
| Net profit | -10 | -12 | -5 | -18 | 12.949 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 504 | 154 | 12.231 | 4.145 | 1.238 |
| Equity | 37 | 25 | 21 | 3 | 715 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 467 | 129 | 12.210 | 4.142 | 523 |
| Total debt | 467 | 129 | 12.210 | 4.142 | 523 |
EBITDA margin
-1218700.0%
This company
15.8%
Market median
-7713391% vs market
20202024
Equity ratio
57.8%
This company
38.2%
Market median
+51% vs market
20202024
Return on equity
1810.1%
This company
18.4%
Market median
+9738% vs market
20202024
Net profit margin
1294872700.0%
This company
8.1%
Market median
+15986082616% vs market
20202024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20202024
Debt / equity
0.73×
This company
0.62×
Market median
+18% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TC Management | Management | 2018 |
FP Management | Management | 2018 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2018 | |
| Company | 50–66.65% | 50–66.65% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FREDERIK MADSEN HOLDING ApS
Cirqle Biomedical Holding ApS Board members of Cirqle Biomedical Holding ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Crouzier | Management | 0 companies |
| Frederik Petursson Madsen | Management | 0 companies |